Genix Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Net Income	-0.34	-0.07	-4.4	-1.07	-1.65
Depreciation & Amortization	-	-	0.55	0.56	0.54
Other Amortization	0	0	0	0	0
Asset Writedown & Restructuring Costs	0.01	-	3.46	-	-
Stock-Based Compensation	-	0.03	0.06	0.26	0.81
Other Operating Activities	0.17	-0.17	0.06	0.04	0
Change in Accounts Receivable	0	-0	0.02	-0.01	0
Change in Inventory	-	-0	0.01	-0.17	-0
Change in Accounts Payable	0.01	0.04	0.03	0.18	-0.09
Change in Other Net Operating Assets	0.02	-0	-0	-0	-0.03
Operating Cash Flow	-0.12	-0.19	-0.22	-0.22	-0.43
Sale (Purchase) of Intangibles	-	-	-	-0	-
Investing Cash Flow	-	-	-	-0	-
Short-Term Debt Issued	0.09	0.19	0.28	0.17	-
Total Debt Issued	0.09	0.19	0.28	0.17	-
Long-Term Debt Repaid	-0.03	-	-	-0.02	-0.01
Total Debt Repaid	-0.03	-	-	-0.02	-0.01
Net Debt Issued (Repaid)	0.06	0.19	0.28	0.15	-0.01
Issuance of Common Stock	0.1	-	-	-	-
Other Financing Activities	-0	-	-0.06	-0.05	-0.12
Financing Cash Flow	0.16	0.19	0.22	0.09	-0.13
Net Cash Flow	0.03	-0	0	-0.13	-0.56
Free Cash Flow	-0.12	-0.19	-0.22	-0.22	-0.43
Free Cash Flow Margin	-	-4624.54%	-1787.27%	-	-
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	-0.01
Cash Interest Paid	-	-	-	0	-
Levered Free Cash Flow	-0.15	-0.53	0.06	0.17	0.68
Unlevered Free Cash Flow	-0.04	-0.46	0.09	0.18	0.68
Change in Working Capital	0.03	0.03	0.06	-0.01	-0.12

Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.